Fibroblast growth factors (FGFs) make up a large family of polypeptide growth factors that are found in organisms ranging from nematodes to humans. In vertebrates, the 22 members of the FGF family range in molecular mass from 17 to 34 kDa and share 13-71% amino acid identity. Between vertebrate species, FGFs are highly conserved in both gene structure and amino-acid sequence. FGFs have a high affinity for heparan sulfate proteoglycans and require heparan sulfate to activate one of four cellsurface FGF receptors. During embryonic development, FGFs have diverse roles in regulating cell proliferation, migration and differentiation. In the adult organism, FGFs are homeostatic factors and function in tissue repair and response to injury. When inappropriately expressed, some FGFs can contribute to the pathogenesis of cancer. A subset of the FGF family, expressed in adult tissue, is important for neuronal signal transduction in the central and peripheral nervous systems.
The prototypical .gf genes contain three coding exons (.igure 1), with exon 1 containing the initiation methionine, but several .gf genes (for example, .gf2 and .gf3) have additional 5 transcribed sequence that initiates from upstream CUG codons [1, 2] . The size of the coding portion of .gf genes ranges from under 5 kb (in .gf3 and .gf4) to over 100 kb (in .gf12). In several .gf subfamilies, exon 1 is subdivided into between two and four alternatively spliced subexons (denoted 1A-1D in the case of .gf8). In these .gf genes, a single initiation codon (ATG) in exon 1A is used. This gene organization is conserved in humans, mouse and zebrafish, but its functional consequences are poorly understood. Other subfamilies of .gfs (such as .gf11-14) have alternative amino termini, which result from the use of alternative 5 exons. It is not known whether a common 5 untranslated exon splices to these exons or whether alternative promoter and regulatory sequences are used.
Most .gf genes are found scattered throughout the genome. In human, 22 .G. genes have been identified and the chromosomal locations of all except .G.16 are known (Table 1 ) [3] [4] [5] [6] [7] . Several human .G. genes are clustered within the genome. .G.3, .G.4 and .G.19 are located on chromosome 11q13 and are separated by only 40 and 10 kb, respectively; .G.6 and .G.23 are located within 55 kb on chromosome 12p13; and .G.17 and .G.20 map to chromosome 8p21-p22. These gene locations indicate that the .G. gene family was generated both by gene and chromosomal duplication and translocation during evolution. Interestingly, a transcriptionally active portion of human .G.7, located on chromosome 15q13-q22, has been amplified to about 16 copies, which are dispersed throughout the human genome [8] .
In the mouse, there are at least 22 .gf genes [3, 9] , and the locations of 16 have been identified (Table 1) . Many of the mouse .gf genes are scattered throughout the genome, but as in the human, .gf3, .gf4 and .gf19 are closely linked (within 80 kb on chromosome 7.) and .gf6 and .gf23 are closely linked on chromosome 6.3-G1.
Evolutionary history
.gfs have been identified in both invertebrates and vertebrates [3] . Interestingly, an .gf-like gene is also encoded in the nuclear polyhedrosis virus genome [10] . .gf-like sequences have not been found in unicellular organisms such as Escherichia coli and Saccharomyces cerevisiae. Although the Drosophila and Caenorhabditis elegans genomes have been sequenced, only one .gf gene (branchless) has been identified in Drosophila [11] and two (egl-17 and let-756) have been identified in C. elegans [12, 13] , in contrast to the large number of .gf genes identified in vertebrates. The evolutionary relationship between invertebrate and vertebrate .gfs is shown in .igure 2a.
The .gf gene expansion has been hypothesized to be coincident with a phase of global gene duplications that took place during the period leading to the emergence of vertebrates [14] . Across species, most orthologous .G. proteins are highly conserved and share greater than 90% amino-acid sequence identity (except human .G. 15 
Characteristic structural features
.G.s range in molecular weight from 17 to 34 kDa in vertebrates, whereas the Drosophila .G. is 84 kDa. Most .G.s share an internal core region of similarity, with 28 highly conserved and six identical amino-acid residues [19] . Ten of these highly conserved residues interact with the .G. receptor (.G.R) [20] . Structural studies on .G.1 and .G.2 identify 12 antiparallel > strands in the conserved core region of the protein (.igure 3) [21, 22] . .G.1 and .G.2 have a > trefoil structure that contains four-stranded > sheets arranged in a triangular array (.igure 3b; reviewed in [23] ). Two > strands (strands >10 and >11) contain several basic amino-acid residues that form the primary heparin-binding site on .G.2. Regions thought to be involved in receptor binding are distinct from regions that bind heparin (.igure 3) [21-24].
Figure 1
Gene structure of selected members of the Fgf family. Only the portion of each gene containing coding exons is shown. Constitutively expressed exons are in black; alternatively spliced exons are in gray. Fgfs 1, 2, 4 and 9 contain the prototypic three-exon organization. For Fgf1, 5' untranslated exons are not shown; inclusion of these exons extends the gene by approximately 69 kb [78] . Fgf8 is an example of a gene with 5' alternative splicing, and Fgf13 demonstrates alternatively used 5' exons separated by over 30 kb. References: Fgf1 [78] ; Fgf2 [79] ; Fgf4 [80] 
Localization and function Localization

Subcellular localization and secretion
Most .G.s (.G.s 3-8, 10, 15, 17-19, and 21-23) have aminoterminal signal peptides and are readily secreted from cells. .G.s 9, 16 and 20 lack an obvious amino-terminal signal peptide but are nevertheless secreted [25] [26] [27] . .G.1 and .G.2 also lack signal sequences, but, unlike .G.9, are not secreted; they can, however, be found on the cell surface and within the extracellular matrix. .G.1 and .G.2 may be released from damaged cells or could be released by an exocytotic mechanism that is independent of the endoplasmic-reticulum-Golgi pathway [28] . .G.9 has been shown to contain a non-cleaved amino-terminal hydrophobic sequence that is required for secretion [29, 30] . A third subset of .G.s (.G.11-14) lack signal sequences and are thought to remain intracellular [31] [32] [33] [34] . It is not known whether these .G.s interact with known .G.Rs or function in a receptor-independent manner within the cell. .G.2 and .G.3 have high-molecular-weight forms that arise from initiation from upstream CUG codons [2, 14, 35] . The additional amino-terminal sequence in these proteins contains nuclear-localization signals, and the proteins can be found in the nucleus; the biological function of nuclear-localized .G. is unclear. 
Important mutants
Many members of the .gf family have been disrupted by homologous recombination in mice. The phenotypes range from very early embryonic lethality to subtle phenotypes in adult mice. The major phenotypes observed in .gf knockout mice are shown in effect of .G.s and .G.Rs on proliferation of some cell types, which was surprising as .G.s were thought to promote proliferation. In vitro studies have now been complemented by gene targeting in mice. The knockout approach has been fairly successful in identifying primary phenotypes but will be challenged by the need to address redundancy amongst the 22 .G.s and to study their developmental and physiological functions after the point of lethality of the null allele.
Unresolved questions
A major unresolved question concerns the mechanism(s) regulating .G. activity in vivo in the presence of cell-surface and extracellular-matrix HSPG. Current hypotheses predict that tissue-specific heparan fragments of defined sequence (and particularly of defined sulfation pattern) will differentially regulate .G.s by controlling their diffusion in the extracellular matrix and their ability to activate specific receptors [77] . These issues will be resolved by determining the sequence of tissue-specific HS and by demonstrating whether specific HS sequences can modulate the binding specificity of .G.s beyond that determined by the specific .G.R and its alternative splice form in the presence of heparin.
A second area of research will aim to elucidate the developmental roles of all the .G.s, first alone and then in various combinations. This will include determining whether a single .G. with a defined developmental function interacts with one or multiple .G.Rs. A third major frontier will be to elucidate the physiological roles of .G.s that are expressed in adult tissues. This will again involve testing combinations of .G.s in cases in which knockouts are viable and designing conditional alleles in cases of embryonic lethality. Major areas being considered include neuronal and cardiovascular physiology, neuronal regeneration and homeostasis and tissue repair.
The last major frontier will be to elucidate the primary roles of .G.s in genetic diseases and cancer. Several .G.s were initially cloned from human and animal tumors. .uture work will be required to determine whether .G. activation is itself an etiological agent in primary human tumors or whether it is a progression factor in the pathogenesis of cancer. As functional roles for .G.s are elucidated in embryonic development, it is expected that various human birth defects and genetic diseases will be attributed to mutations in .gf genes. These studies will probably lead to the development of pharmacogenetic agents to treat these diseases.
Because a large number of skeletal diseases are caused by mutations in .gfr genes, it is anticipated that mutations in some .gf genes will also be involved in skeletal pathology. Identification of an FGF3 CUG initiation site. This amino-terminal extended product is localized in both the nucleus/nucleolus and secretory pathway. The amino terminus contains both a signal sequence and a nuclear localization signal. 
